US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
PT973804E
(pt)
*
|
1997-04-07 |
2007-03-30 |
Genentech Inc |
Anticorpos anti-vegf
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
ES2236634T3
(es)
*
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6455283B1
(en)
|
1998-03-17 |
2002-09-24 |
Genentech, Inc. |
Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
|
CA2347833A1
(en)
|
1998-11-18 |
2000-05-25 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US6346249B1
(en)
*
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
EP1881004B1
(de)
|
2000-04-21 |
2012-07-25 |
Fuso Pharmaceutical Industries, Ltd. |
Neuartiges Collectin
|
EP2792747A1
(de)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
EP2075253A1
(de)
|
2000-06-23 |
2009-07-01 |
Genentech, Inc. |
Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
MXPA04007583A
(es)
*
|
2002-02-11 |
2005-04-25 |
Genentech Inc |
Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
|
US7456260B2
(en)
|
2002-06-17 |
2008-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized antibody
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
KR20170073698A
(ko)
|
2003-05-30 |
2017-06-28 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
EP1660534A2
(de)
*
|
2003-08-22 |
2006-05-31 |
MedImmune, Inc. |
Humanisierung von antikörpern
|
PL1697507T3
(pl)
|
2003-12-02 |
2013-03-29 |
Pasteur Institut |
Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS
|
EP3653641A1
(de)
|
2004-02-19 |
2020-05-20 |
Genentech, Inc. |
Antikörper mit korrigiertem cdr
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
CA2584305A1
(en)
|
2004-10-21 |
2006-05-04 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
TWI557138B
(zh)
|
2006-01-20 |
2016-11-11 |
建南德克公司 |
抗-ephrinb2抗體及使用該抗體的方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
EA017303B1
(ru)
*
|
2006-05-25 |
2012-11-30 |
Глаксо Груп Лимитед |
Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
|
SG175615A1
(en)
|
2006-06-06 |
2011-11-28 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
CN1903880B
(zh)
*
|
2006-08-02 |
2010-05-12 |
中国人民解放军军事医学科学院基础医学研究所 |
抗肿瘤血管内皮生长因子vegf-e抗原及其编码基因与应用
|
SG174090A1
(en)
|
2006-08-21 |
2011-09-29 |
Hoffmann La Roche |
Tumor therapy with an anti-vegf antibody
|
CN101148474B
(zh)
*
|
2006-09-21 |
2014-06-11 |
上海杰隆生物工程股份有限公司 |
人源人血管内皮生长因子单克隆抗体及其制备方法
|
KR20150097813A
(ko)
|
2006-12-19 |
2015-08-26 |
제넨테크, 인크. |
조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
|
MX2009012421A
(es)
|
2007-05-17 |
2009-12-01 |
Genentech Inc |
Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
|
US8318163B2
(en)
|
2007-05-17 |
2012-11-27 |
Genentech, Inc. |
Anti-pan neuropilin antibody and binding fragments thereof
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
DK2215117T4
(en)
|
2007-10-30 |
2018-04-09 |
Genentech Inc |
ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
|
EP2217261B1
(de)
|
2007-11-09 |
2015-10-07 |
Genentech, Inc. |
Activin-rezeptor-like-kinase-1-antagonist-zusammensetzungen und anwendungsverfahren
|
TWI468417B
(zh)
*
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
AU2009264565C1
(en)
*
|
2008-06-25 |
2022-01-27 |
Novartis Ag |
Stable and soluble antibodies inhibiting VEGF
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
RU2536937C2
(ru)
|
2008-10-14 |
2014-12-27 |
Дженентек, Инк. |
Варианты иммуноглобулина и их применения
|
EP2358746B1
(de)
|
2008-11-03 |
2020-09-16 |
Molecular Partners AG |
Bindungsproteine zum hemmen der vegf-a-rezeptorinteraktion
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
SG187385A1
(en)
|
2008-12-23 |
2013-02-28 |
Genentech Inc |
Methods and compositions for diagnostic use in cancer patients
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
US20120093811A1
(en)
*
|
2009-04-03 |
2012-04-19 |
Simmonds Jason W |
Anti-vegf-d antibodies
|
EP2417156B1
(de)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalente, bispezifische antikörper
|
WO2010129609A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
Antibodies and methods of use thereof
|
CA2838400A1
(en)
|
2009-05-08 |
2010-11-11 |
Genentech, Inc. |
Humanized anti-egfl7 antibodies and methods using same
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
JP5785941B2
(ja)
*
|
2009-06-17 |
2015-09-30 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗vegf抗体とその使用
|
CN102482715A
(zh)
|
2009-07-13 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
用于癌症治疗的诊断方法和组合物
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
TW201431558A
(zh)
|
2009-08-15 |
2014-08-16 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
AU2010292060A1
(en)
|
2009-09-11 |
2012-04-12 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
AU2010297344A1
(en)
|
2009-09-17 |
2012-02-23 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
CN102051396B
(zh)
*
|
2009-11-04 |
2014-07-16 |
无锡天演生物技术有限公司 |
雁阵式定域随机突变方法及其在单抗分子进化技术中的应用
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
KR20190067275A
(ko)
|
2009-12-21 |
2019-06-14 |
제넨테크, 인크. |
항체 제제
|
RU2559542C2
(ru)
|
2009-12-23 |
2015-08-10 |
Дженентек, Инк. |
Антитела против bv8 и их применение
|
FR2955773B1
(fr)
|
2010-02-01 |
2017-05-26 |
Commissariat A L'energie Atomique |
Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
|
MA34059B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Thérapie anti-angiogénique pour le traitement du cancer des ovaires
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
CN102863533B
(zh)
*
|
2010-06-21 |
2013-12-11 |
中国科学技术大学 |
抗体人源化改造方法
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
JP2013538338A
(ja)
|
2010-07-19 |
2013-10-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
SG187120A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
NZ703919A
(en)
|
2010-11-15 |
2016-04-29 |
Five Prime Therapeutics Inc |
Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
ES2899186T3
(es)
*
|
2010-12-31 |
2022-03-10 |
Bioatla Inc |
Humanización rápida de anticuerpos
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
SG193554A1
(en)
|
2011-03-29 |
2013-11-29 |
Roche Glycart Ag |
Antibody fc variants
|
CN104586861A
(zh)
|
2011-04-01 |
2015-05-06 |
基因泰克公司 |
Akt抑制剂化合物和阿比特龙的组合及使用方法
|
WO2012145539A1
(en)
|
2011-04-20 |
2012-10-26 |
Acceleron Pharma, Inc. |
Endoglin polypeptides and uses thereof
|
WO2012151317A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
EP2732269B1
(de)
|
2011-07-12 |
2017-10-18 |
Epitomics, Inc. |
Facs-basiertes verfahren zur erzeugung einer antikörpersequenz
|
JP2014525412A
(ja)
|
2011-08-17 |
2014-09-29 |
ジェネンテック, インコーポレイテッド |
難治性腫瘍における血管新生の阻害
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
SI2825558T1
(sl)
|
2012-03-13 |
2019-08-30 |
F. Hoffmann-La Roche Ag |
Kombinirana terapija za zdravljenje raka jajčnikov
|
EP3556776A1
(de)
|
2012-05-31 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindungsantagonisten und vegf-antagonisten
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
KR20150038593A
(ko)
|
2012-08-07 |
2015-04-08 |
제넨테크, 인크. |
교모세포종의 치료를 위한 조합 요법
|
CA2890190A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
AU2013344464A1
(en)
|
2012-11-16 |
2015-05-21 |
The Regents Of The University Of California |
Pictet-Spengler ligation for protein chemical modification
|
FR2998579B1
(fr)
|
2012-11-27 |
2015-06-19 |
Commissariat Energie Atomique |
Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US10414820B2
(en)
*
|
2013-03-13 |
2019-09-17 |
Imaginab, Inc. |
Antigen binding constructs to CD8
|
EP3744345B1
(de)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antikörperformulierungen
|
EP2999799A4
(de)
|
2013-05-23 |
2016-12-28 |
Five Prime Therapeutics Inc |
Verfahren zur behandlung von karzinomen
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
EP3055329B1
(de)
|
2013-10-11 |
2018-06-13 |
F. Hoffmann-La Roche AG |
Multispezifische antikörper mit domänengetauschten, gemeinsamen, variablen leichten ketten
|
CN105899225A
(zh)
|
2013-10-25 |
2016-08-24 |
阿塞勒隆制药公司 |
用于治疗纤维化疾病的内皮联蛋白肽
|
EP3071181B1
(de)
|
2013-11-18 |
2021-03-24 |
Formycon AG |
Pharmazeutische zusammensetzung einen anti-vegf-antikörper enthaltend
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
SG10201804945WA
(en)
*
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
RS60031B1
(sr)
|
2013-12-20 |
2020-04-30 |
Hoffmann La Roche |
Humanizovana anti-tau(ps422) antitela i načini upotrebe
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CU24481B1
(es)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
Moléculas de anticuerpo que se unen a lag-3
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
EP3828202A1
(de)
|
2014-05-12 |
2021-06-02 |
Formycon AG |
Vorgefüllte spritze aus kunststoff mit einem vegf-antagonisten
|
CN106456608B
(zh)
|
2014-06-06 |
2020-08-28 |
雷德伍德生物科技股份有限公司 |
抗her2抗体-美登木素缀合物及其使用方法
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
JP2017523776A
(ja)
|
2014-07-14 |
2017-08-24 |
ジェネンテック, インコーポレイテッド |
膠芽腫の診断方法及びその治療用組成物
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
MX2017003121A
(es)
|
2014-09-15 |
2017-08-02 |
Genentech Inc |
Formulaciones de anticuerpos.
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
CA2959821A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
EP3237639A2
(de)
|
2014-12-23 |
2017-11-01 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von chemotherapieresistentem krebs
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
AR105089A1
(es)
*
|
2015-06-24 |
2017-09-06 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
KR20180050321A
(ko)
|
2015-08-07 |
2018-05-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
EP3922649B1
(de)
|
2015-10-30 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Anti-htra1-antikörper und verfahren zur verwendung davon
|
US10894830B2
(en)
|
2015-11-03 |
2021-01-19 |
Janssen Biotech, Inc. |
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
|
US20190209697A1
(en)
|
2015-11-05 |
2019-07-11 |
The Regents Of The University Of California |
Cells labelled with lipid conjugates and methods of use thereof
|
AU2016356717B2
(en)
|
2015-11-18 |
2022-09-29 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
MX2018006171A
(es)
|
2015-11-18 |
2018-12-19 |
Formycon Ag |
Jeringa de plastico precargada que contiene un antagonista de vegf.
|
JP6882738B2
(ja)
|
2015-11-18 |
2021-06-02 |
フォーマイコン アーゲーFormycon Ag |
Vegf阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
BR112018013407A2
(pt)
|
2015-12-30 |
2018-12-18 |
Kodiak Sciences Inc |
anticorpos e conjugados dos mesmos
|
EP3407868A1
(de)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Flüssigformulierung eines vegf-antagonisten
|
CN105481981B
(zh)
*
|
2016-01-27 |
2019-03-19 |
中国人民解放军第二军医大学 |
靶向vegf双特异性抗体及其用途
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
TWI823836B
(zh)
|
2016-07-08 |
2023-12-01 |
美商建南德克公司 |
人類副睪蛋白4(he4)用於評定癌症治療反應性之用途
|
EP3481963A1
(de)
|
2016-07-08 |
2019-05-15 |
Genentech, Inc. |
Verfahren zur diagnose und behandlung von krebs mittels des expressionsstatus und mutationsstatus von nrf2 und nachgeschalteten zielgenen dieses gens
|
CA3032542A1
(en)
|
2016-08-12 |
2018-02-15 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
EP3783022A3
(de)
*
|
2016-08-23 |
2021-06-30 |
MedImmune Limited |
Anti-vegf-a-antikörper und verwendungen davon
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EA202090104A1
(ru)
|
2017-06-22 |
2020-04-09 |
Новартис Аг |
Молекулы антител к cd73 и пути их применения
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
EP3731865A1
(de)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Verfahren zur verbesserung der vegf-rezeptor-blockierenden selektivität eines anti-vegf-antikörpers
|
WO2019173692A2
(en)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
KR20200144116A
(ko)
|
2018-04-16 |
2020-12-28 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
암 치료의 부작용을 예방하거나 치료하기 위한 방법
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3867646A1
(de)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
US20220185875A1
(en)
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
EP3956022A1
(de)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von prostatakrebs mit einem anti-psma-cd3-antikörper
|
TW202108616A
(zh)
|
2019-05-03 |
2021-03-01 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
WO2020227554A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Genentech, Inc. |
Methods of making antibodies
|
WO2021026685A1
(zh)
|
2019-08-09 |
2021-02-18 |
安徽瀚海博兴生物技术有限公司 |
一种新型结构的抗vegf-抗pd1双特异性抗体
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
JP2023517345A
(ja)
|
2020-03-13 |
2023-04-25 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン-33抗体及びその使用
|
CN113461824A
(zh)
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
FR3110838B1
(fr)
|
2020-05-28 |
2022-06-24 |
Commissariat Energie Atomique |
Complexe immunomodulateur et ses applications pour la thérapie
|
CA3182607A1
(en)
|
2020-06-30 |
2022-01-06 |
Erik Hans MANTING |
Use of leukemia-derived cells in ovarian cancer vaccines
|
CN114106190A
(zh)
|
2020-08-31 |
2022-03-01 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
AU2021377810A1
(en)
|
2020-11-13 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
|
JP2024506249A
(ja)
|
2021-01-22 |
2024-02-13 |
メンドゥス・ベスローテン・フェンノートシャップ |
腫瘍ワクチン接種の方法
|
AU2022214491A1
(en)
|
2021-01-28 |
2023-09-14 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
EP4330436A1
(de)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutische und diagnostische verfahren und zusammensetzungen gegen krebs
|
EP4363449A2
(de)
|
2021-07-02 |
2024-05-08 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur behandlung von krebs
|
CA3224180A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2024062076A1
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
WO2024062082A1
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
WO2024062072A2
(en)
|
2022-09-21 |
2024-03-28 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|